Logo
x

Search category

Subscribe Now

incyte

Incyte to Acquire Escient Pharmaceuticals and its MRGPR Antagonist Assets

Incyte to Acquire Escient Pharmaceuticals and its MRGPR Antagonist Assets

  • April 24, 2024
Incyte and China Medical System Sign a Collaboration & License Agreement for Povorcitinib Use in Autoimmune and Inflammatory Dermatologic Indications

Incyte and China Medical System Sign a Collaboration & License Agreement for Povorcitinib Use in Autoimmune and Inflammatory Derma...

  • April 2, 2024
Incyte Highlights Results from the P-II Trial of Povorcitinib for the Treatment of Prurigo Nodularis at AAD’24

Incyte Highlights Results from the P-II Trial of Povorcitinib for the Treatment of Prurigo Nodularis at AAD’24

  • March 11, 2024
Incyte Reports the US FDA’s Acceptance of BLA for Axatilimab with Priority Review to Treat Chronic Graft-Versus-Host Disease (GVHD)

Incyte Reports the US FDA’s Acceptance of BLA for Axatilimab with Priority Review to Treat Chronic Graft-Versus-Host Disease (GVHD...

  • February 28, 2024
PharmaShots Weekly Snapshots (October 09–13, 2023) _

PharmaShots Weekly Snapshots (October 09–13, 2023) _

  • October 14, 2023
Incyte Presents Positive 52-Week P-IIb Trial Results of Povorcitinib (INCB54707) for Extensive Nonsegmental Vitiligo at EADV 2023

Incyte Presents Positive 52-Week P-IIb Trial Results of Povorcitinib (INCB54707) for Extensive Nonsegmental Vitiligo at EADV 2023

  • October 12, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.